PTC/S8/08a(04-07)
Approved for use through 7/31/2005 OMB 0651-0031
Petent & Trademerk Office, U.S. DEPARTMENT OF CONDUCTOR

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information Substitute for form 1449A/PTO INFORMATION DISCLOSURE Complete if Known STATEMENT BY APPLICANT **Application Number** 10/516,757 **Filing Date** December 4, 2004 First Named Inventor Rabussay, Dietmar **Art Unit TBA Examiner Name TBA** (Use as many sheets as necessary) Attorney Docket No: GTI-1490-US Sheet

			US PAT	ENT DOCUMENTS	
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate
	_ 1	3523907	08/11/1970	VRANCKEN et al	
	2	5171568	12/15/1992	BURKE et al	

			FOREIGN	PATENT DOCUMENTS	
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T²
	3	WO 89/04669	06/01/1989	HOUGHTON et al	- ·· · <u></u>
	4	WO 90/11089	10/04/1990	HOUGHTON et al	
	5	WO 90/14436	11/29/1990	HOUGHTON et al	
	6	WO 90/14837	12/13/1990	VAN NEST et al	

Examiner	Cite	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Τť
initials*	No 1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	7	BAER et al, "DNA Sequence and Expression of the B95-8 Eostein Barr Virus Genome." Nature 310:207-211 (1984)	 -
	8	CHEE et al, "Analysis of the protein-coding content of the sequence of human cytomegaloviruses strain AD169," Curr Top Microbiol Immunol. 154:125-169	T
	9	DAVISON et al, "The complete DNA sequence of varicella-zoster virus," J. Gen. Virol. 67:1759-1816 (1986)	╁
	10	DUE et al, "Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans," Eur. J. Immunol. 24(10):2369-2376 (1994)	
	11	ERICKSON et al "Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis," J. Immunol. 151:4189-4199 (1993)	<u> </u>
	12	HOUGHTON et al, "Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease," Hepatology 14(2):381-388 (1991)	\vdash
	13	JEFFERY et al, "The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique," <i>Pharm Res.</i> 10(3):362-368 (1993)	
	14	KAWAOKA et al, "Molecular characterization of a new hemagglutinin, subtype H14, of influenza A virus," Virology 179:759-767 (1990)	
	15	MCGEOCH et al, *The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type, * J. Gen. Virol. 69:1531-1574 (1988)	
	16	MIZUSHIMA et al, "pEF-BOS, a Powerful Mammalian Expression Vector," Nucleic Acids Research 18(17):5322 (1990)	
	17	MODROW et al, "Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions," <i>J. Virology</i> 61:570-578 (1987)	T
	18	MORIARTY et al, "Expression of the Hepatitis B Virus Surface Antigen Gene in Cell Culture by Using a Simian Virus 40 Vector," Proc. Natl. Acad. Sci. (USA) 78(4):2608-2610 (1981)	
	19	O'HAGAN et al, "Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles," Vaccine 11:965-969 (1993)	1
	20	OGAWA et al, "A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid," Chem. Pharm. Bull. 36:1095-1103 (1988)	T
	21	OTT et al, "MF-59—Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines," in POWELL et al, Vaccine Design: The Subunit and Adjuvant Approach Plenum Press, New York pp. 277-296 (1995)	
	22	REMINGTON The Science and Practice of Pharmacy, Mack Publishing Company, Easton, PA, 19 th Edition (1995)	1

EXAMINER

DATE CONSIDERED

PTO/SB/08a(04-07) or use through 7/31/2006 OMB 0551-0031

Substi	itute for form 1449/	VPTO		Onder the Properties a Recognition Act of 1995, no persons are re	US Petert & Transman Office, U.S. DEPARTMENT OF COMMER equired to respond to a collection of information unless it contains a valid OMB control numb
		DISCLOS			Complete If Known
STA	TEMENT E	Y APPLICA	ANT	Application Number	10/516,757
				Filing Date	December 4, 2004
				First Named Inventor	Rabussay, Dietmar
				Art Unit	TBA
				Examiner Name	TBA
	(Use as many sho	eets as necessary)			
Sheet	2	of		Attorney Docket No: 0	GTI-1490-US

	·	23	VAN NEST et al, "Advanced adjuvant formulations for use with recombinant subunit vaccines," in BROWN et al, Vaccines 92, Modern Approaches to New Vaccines Cold Springs Harbor Laboratory Press pp. 57-62 (1992)	
- 1	-	24	WERSTER of all "Actions in which the second of the second	
- 1			WEBSTER et al, "Antigenic variation among type A influenza viruses," p. 127-168. In: alese et al (ed.), Genetics of	
L		l	influenza viruses. Springer-Verlag, New York	ſ
_			ger rendg, row rom	

PTO/E3/08/Q06-03)
Approved for use through 07/31/2008, OMB 0551-0031
ford 6 Teclamon Office: U.S. DEPARTMENT OF A

INFORMATION DISCLOS STATEMENT BY APPLICAN PE

U	der the Pepersons Reduction Act of 1995, no persons are n	US Prior & Trademark Office: U.S. DEPARTMENT OF COSMICE CO. Pour de composit de composit de company de compan
	Complete if Known	
	Application Number	1 6,757
	Filing Date	December 4, 2004
	First Named Inventor	Rabussay, Dietmar P.
١	Group Art Unit	To Be Assigned
l	Examiner Name	To Be Assigned
<i></i>	Attorney Docket No: G	STI-1490-US

Sheet 1 of 1		E/
	CA PE	MESS

				,	
			US PATENT	DOCUMENTS	
Examiner Initials *	Cite No.	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	US 6,120,493	19 Sep 2000	Hoffman	
	A2.	US 5,810,762	22 Sep 1998	Hofmann	
	A3.	US 5,439,440	08 Aug 1995	Hofmann	
	A4.	US 5,273,525	28 Dec 1993	Hofmann	
	A5.	US 5,128,257	07 Jul 1992	Baer	

		FORE	IGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.'	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	72
	A6.	WO 01/07585 A	01 Feb 2001	Regents Univ. of CA		
	A7.	WO 99/22810	14 May 1999	Hisamitsu Pharm. Co.	•	

	OTH	ER DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner initials*	Cite No 1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
	A8.	BOON, T., "Teaching the immune system to fight cancer," <i>Scientific American</i> 268(3):82-89 (March 1993)	
	A9.	DEV et al., "Medical applications of electroporation," <i>IEEE Transactions on plasma science</i> , 28(1):206-223 (2000)	
	A10.	FEWELL et al., "Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation," Molecular Therapy 3:574-583 (2000)	
	A11.	GLASSPOOL-MALONE et al., "Efficient nonviral cutaneous transfection," Molecular Therapy 2:140-146 (2000)	
	A12.	HOFMANN et al., "Electroporation therapy of solid tumors," Critical Reviews in Therapeutic Drug Carrier Systems 16(6):523-569 (1999)	
	A13.	TOMOV et al., "Are the stainless steel electrodes inert?," Bioelectrochemistry 51(2):207-209 (2000)	
	A14.	ZELPHATI et al., "PNA-dependent gene chemistry: stable coupling of peptides and oligonucleotides to plasmid DNA, <i>Biotechniques</i> 28:304-310; 312-314; 316 (2000)	
	A15.	ZHANG et al., "Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation," Biochim. Biophys. Acta 1572(1):1-9 (2002)	

EXAMINER

DATE CONSIDERED